Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

[1]  P. Dawson,et al.  Intestinal cholesterol absorption. , 1999, Current opinion in lipidology.

[2]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[3]  J. Clader,et al.  Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. , 1998, Journal of medicinal chemistry.

[4]  H. Davis,et al.  In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. , 1997, The Journal of pharmacology and experimental therapeutics.

[5]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[6]  A. Somogyi,et al.  The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. , 1996, Drug metabolism reviews.

[7]  R. Miller,et al.  Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  R. Burrier,et al.  Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. , 1995, Atherosclerosis.

[9]  R. Burrier,et al.  Effect of the cholesterol absorption inhibitor SCH48461 in combination with the HMG-CoA reductase inhibitor lovastatin in rabbits, dogs and rhesus monkeys , 1994 .

[10]  R. Burrier,et al.  SCH 48461, a novel inhibitor of cholesterol absorption , 1994 .

[11]  R. Burrier,et al.  2-Azetidinones as inhibitors of cholesterol absorption. , 1994, Journal of medicinal chemistry.

[12]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[13]  P. B. Marsh.  Implications for Reducing Chronic Disease Risk . 1989. Anon. National Academy Press, National Research Council, 2101 Constitution Avenue, NW, Washington, DC. 749 pp. , 1991 .

[14]  D. Back,et al.  Review: first‐pass metabolism by the gastrointestinal mucosa , 1987, Alimentary pharmacology & therapeutics.

[15]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[16]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[17]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.